The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 343:1217-1222 October 26, 2000 Number 17
NextNext

A Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II or IIIa Non–Small-Cell Lung Cancer
Steven M. Keller, M.D., Sudeshna Adak, Ph.D., Henry Wagner, M.D., Arnold Herskovic, M.D., Ritsuko Komaki, M.D., Burke J. Brooks, M.D., Michael C. Perry, M.D., Robert B. Livingston, M.D., David H. Johnson, M.D., for The Eastern Cooperative Oncology Group

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background We conducted a randomized trial to determine whether combination chemotherapy plus thoracic radiotherapy is superior to thoracic radiotherapy alone in prolonging survival and preventing local recurrence in patients with completely resected stage II or IIIa non–small-cell lung cancer.

Methods After surgical staging and resection of the tumor (usually by lobectomy or pneumonectomy), the patients were randomly assigned to receive either four 28-day cycles of cisplatin (60 mg per square meter of body-surface area intravenously on day 1) and etoposide (120 mg per square meter intravenously on days 1, 2, and 3) administered concurrently with radiotherapy (a total of 50.4 Gy, given in 28 daily fractions) or radiotherapy alone (a total of 50.4 Gy, given in 28 daily fractions).

Results Of the 488 patients who were enrolled in the study, 242 were assigned to receive radiotherapy alone and 246 were assigned to receive chemotherapy and radiotherapy. The median duration of follow-up was 44 months. Treatment-associated mortality was 1.2 percent in the group given radiotherapy alone and 1.6 percent in the group given chemotherapy and radiotherapy. The median survival was 39 months in the group given radiotherapy and 38 months in the group given chemotherapy and radiotherapy (P= 0.56 by the log-rank test). The relative likelihood of survival among patients assigned to receive chemotherapy and radiotherapy, as compared with those assigned to receive radiotherapy alone, was 0.93 (95 percent confidence interval, 0.74 to 1.18). Intrathoracic disease recurred within the radiation field in 30 of 234 patients (13 percent) in the group given radiotherapy and in 28 of 236 patients (12 percent) in the group given chemotherapy and radiotherapy (P=0.84); data on recurrence were not available for 18 patients.

Conclusions As compared with radiotherapy alone, adjuvant radiotherapy and chemotherapy with cisplatin and etoposide does not decrease the risk of intrathoracic recurrence or prolong survival in patients with completely resected stage II or IIIa non–small-cell lung cancer.


Source Information

From the Department of Surgery, Beth Israel Medical Center, New York (S.M.K.); the Department of Biostatistics, Dana–Farber Cancer Institute, Boston (S.A.); the Department of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, Fla. (H.W.); the Department of Radiation Oncology, Oakwood Hospital, Detroit (A.H.); the Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston (R.K.); the Division of Medical Oncology, Ochsner Clinic, Baton Rouge, La. (B.J.B.); the Division of Hematology and Medical Oncology, University of Missouri, Ellis Fischer Cancer Center, Columbia (M.C.P.); the Division of Medical Oncology, University of Washington, Seattle (R.B.L.); and the Division of Medical Oncology, Vanderbilt University, Nashville (D.H.J.).

Address reprint requests to Dr. Keller at the Department of Surgery, Beth Israel Medical Center, First Ave. and 16th St., New York, NY 10003, or at skeller{at}bethisraelny.org.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.